Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nab-sirolimus + gemcitabine
- Development stage
- Phase 1
- Lead developer
- Aadi Bioscience
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
nab-sirolimus + gemcitabine is an investigational combination therapy consisting of **nab-sirolimus**, a nanoparticle albumin-bound formulation of the mTOR inhibitor sirolimus, and **gemcitabine**, a nucleoside analog cytotoxic chemotherapy agent. The combination aims to exploit synergistic antitumor effects, particularly in sarcomas with TSC1 or TSC2 loss-of-function mutations. Nab-sirolimus inhibits the mammalian target of rapamycin (mTOR) pathway, which is frequently hyperactivated in TSC-mutant tumors, while gemcitabine interferes with DNA synthesis, leading to cytotoxicity. The combination is being studied primarily in advanced leiomyosarcomas and soft tissue sarcomas, especially those bearing TSC mutations, and is undergoing Phase I clinical evaluation to determine safety, tolerability, efficacy, and recommended dosing[1][3][5][7].
- Other names
- gemcitabine + nab-sirolimus
02
Targets
DNAmTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on nab-sirolimus + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nab-sirolimus + gemcitabine.